Baird Medical Investment Holdings Limited (BDMD) Stock Score, Valuation & Financial Research
Baird Medical Investment Holdings Limited is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 17/100.
Quick answer for BDMD
Baird Medical Investment Holdings Limited currently has a Wall Street Score of 17/100. The stored market price is $1.1. Its financial score is 4/100. Its valuation score is 0/100. The latest WSS change is +0.3 points. These figures are a research snapshot, not a buy or sell recommendation.
What Baird Medical Investment Holdings Limited does
Based in China, Baird Medical Investment Holdings Limited and its associated entities specialize in engineering and commercializing microwave ablation medical apparatus. These sophisticated instruments are employed in the minimally invasive management of a diverse array of benign and malignant tumors, notably targeting thyroid nodules, hepatic carcinomas, pulmonary cancers, and mammary lesions. The organization was established in 2012, with its corporate headquarters situated in Guangzhou, China.
BDMD financial snapshot
- Wall Street Score:
- 17/100
- Current price:
- $1.1
- Market capitalization:
- $46.4M
- Revenue:
- $56.4M
- Net income:
- $-19.1M
- Free cash flow:
- $-1.4M
- Cash:
- $289K
- Total debt:
- $14.2M
- EPS:
- -0.60
- Financial score:
- 4/100
- Valuation score:
- 0/100
- Revenue score:
- 32/100
What stands out
- Reported year-over-year revenue growth is +1.5%.
- Free cash flow is $-1.4M, showing cash burn in the current stored period.
- The balance sheet shows $289K of cash versus $14.2M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.3 points: BDMD increased 0.3 points because Asset improved by 3.9 points.
- The current research record carries a corporate distress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 4/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BDMD
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.